TP53 mutations in HCC (~30%) — adverse prognostic; not directly targeted.
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-TP53-MUT-HCC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-HCC |
| Sources | SRC-AASLD-HCC-2023 SRC-CIVIC SRC-NCCN-HCC-2025 |
Actionability Facts
| Biomarker | BIO-TP53-MUTATION |
|---|---|
| Variant | any pathogenic |
| Disease | DIS-HCC |
| ESCAT tier | IIIB |
| Evidence summary | TP53 mutations in HCC (~30%) — adverse prognostic; not directly targeted. |
Notes
ESCAT IIIB.
Used By
No reverse references found in the YAML corpus.